- Home
- AMS vs MNPR Comparison
AMS vs MNPR Comparison
Compare AMS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- MNPR
- Stock Information
- Founded
- AMS 1980
- MNPR 2014
- Country
- AMS United States
- MNPR United States
- Employees
- AMS N/A
- MNPR N/A
- Industry
- AMS Medical Specialities
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- MNPR Health Care
- Exchange
- AMS Nasdaq
- MNPR Nasdaq
- Market Cap
- AMS 19.5M
- MNPR 16.3M
- IPO Year
- AMS N/A
- MNPR 2019
- Fundamental
- Price
- AMS $3.09
- MNPR $17.94
- Analyst Decision
- AMS
- MNPR Strong Buy
- Analyst Count
- AMS 0
- MNPR 3
- Target Price
- AMS N/A
- MNPR $27.33
- AVG Volume (30 Days)
- AMS 19.9K
- MNPR 1.5M
- Earning Date
- AMS 11-13-2024
- MNPR 11-08-2024
- Dividend Yield
- AMS N/A
- MNPR N/A
- EPS Growth
- AMS 566.31
- MNPR N/A
- EPS
- AMS 0.66
- MNPR N/A
- Revenue
- AMS $23,104,000.00
- MNPR N/A
- Revenue This Year
- AMS $29.39
- MNPR N/A
- Revenue Next Year
- AMS $16.22
- MNPR N/A
- P/E Ratio
- AMS $4.30
- MNPR N/A
- Revenue Growth
- AMS 13.49
- MNPR N/A
- 52 Week Low
- AMS $2.32
- MNPR $1.37
- 52 Week High
- AMS $4.60
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- AMS 47.64
- MNPR 59.78
- Support Level
- AMS $2.85
- MNPR $16.26
- Resistance Level
- AMS $3.24
- MNPR $19.70
- Average True Range (ATR)
- AMS 0.14
- MNPR 2.07
- MACD
- AMS -0.02
- MNPR -0.08
- Stochastic Oscillator
- AMS 58.54
- MNPR 72.29
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.